Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
17alpha-picolyl-androsta-3,5-dien-17beta-ol is a synthetic heterocyclic steroidal derivative belonging to the androstane class. It features a picolyl (2-pyridylmethyl) substituent at the 17α position and a 3,5-diene system within the steroid nucleus. This compound is primarily investigated for its potent antineoplastic properties, particularly against triple-negative breast cancer (TNBC) cell lines such as MDA-MB-231. Its mechanism of action involves the induction of apoptotic cell death and the modulation of the cell cycle, leading to significant growth inhibition. As a non-hormonal steroidal agent, it is designed to bypass the need for estrogen, progesterone, or HER2 receptors, offering a potential targeted therapy for aggressive breast cancer subtypes that are resistant to conventional endocrine treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 17alpha-picolyl-androsta-3,5-dien-17beta-ol.